# 134 - Drug interactions

# Drug interactions

Depression and anxiety disorders
CHAPTER 3
15. Roehrs T, et al. Drug-­related sleep stage changes: functional significance and clinical relevance. Sleep Med Clin 2010; 5:559–570.
16. Yue JL, et al. Efficacy and tolerability of pharmacological treatments for insomnia in adults: a systematic review and network meta-­analysis. 
Sleep Med Rev 2023; 68:101746.
17. Wilson S, et al. British Association for Psychopharmacology consensus statement on evidence-­based treatment of insomnia, parasomnias and 
circadian rhythm disorders: an update. J Psychopharmacol 2019; 33:923–947.
18. Hallahan BP, et al. Benzodiazepine and hypnotic prescribing in an acute adult psychiatric in-­patient unit. Psychiatr Bull 2009; 33:12–14.
19. Mahomed R, et  al. Prescribing hypnotics in a mental health trust: what consultants say and what they do. Pharmaceutical J 2002; 
268:657–659.
20. Benasi G, et al. Benzodiazepines as a monotherapy in depressive disorders: a systematic review. Psychother Psychosom 2018; 87:65–74.
21. Shiwaku H, et al. Benzodiazepines reduce relapse and recurrence rates in patients with psychotic depression. J Clin Med 2020; 9:1938.
22. Ogawa Y, et al. Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database Syst Rev 2019; 6:CD001026.
23. Department of Health and Social Care. A National Service Framework for Mental Health: Modern standards and service models. London: 
DHSC; 1999 (last accessed February 2025); https://www.gov.uk/government/publications/quality-­standards-­for-­mental-­health-­services.
24. Bushnell GA, et al. Simultaneous antidepressant and benzodiazepine new use and subsequent long-­term benzodiazepine use in adults with 
depression, United States, 2001–2014. JAMA Psychiatry 2017; 74:747–755.
25. Patel MX, et al. Joint BAP NAPICU evidence-­based consensus guidelines for the clinical management of acute disturbance: de-­escalation and 
rapid tranquillisation. J Psychopharmacol 2018; 32:601–640.
26. Zaman H, et al. Benzodiazepines for psychosis-­induced aggression or agitation. Cochrane Database Syst Rev 2017; 12:CD003079.
27. Dold M, et al. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev 2012; 11:CD006391.
28. Sim F, et al. Re-­examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review. J Psychopharmacol 2015; 
29:212–223.
29. Paton C, et al. Benzodiazepines in schizophrenia. Is there a trend towards long-­term prescribing? Psychiatr Bull 2000; 24:113–115.
30. Dold M, et al. Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-­analysis and Cochrane review of randomized 
controlled trials. Eur Neuropsychopharmacol 2013; 23:1023–1033.
31. Bergman H, et al. Benzodiazepines for antipsychotic-­induced tardive dyskinesia. Cochrane Database Syst Rev 2018; 1:CD000205.
32. Huff C, et  al. Enduring neurological sequelae of benzodiazepine use: an Internet survey. Ther Adv Psychopharmacol 2023; 
13:20451253221145561.
33. Crowe SF, et  al. The residual medium and long-­term cognitive effects of benzodiazepine use: an updated meta-­analysis. Arch Clin 
Neuropsychol 2017; 33:901–911.
34. Poly TN, et al. Association between benzodiazepines use and risk of hip fracture in the elderly people: a meta-­analysis of observational studies. Joint Bone Spine 2020; 87:241–249.
35. Barbone F, et al. Association of road-­traffic accidents with benzodiazepine use. Lancet 1998; 352:1331–1336.
36. Rudisill TM, et al. Medication use and the risk of motor vehicle collisions among licensed drivers: a systematic review. Accid Anal Prev 2016; 
96:255–270.
37. Albrecht B, et al. Benzodiazepine use and aggressive behaviour: a systematic review. Aust N Z J Psychiatry 2014; 48:1096–1114.
38. Kim DH, et al. Use of hypnotics and risk of cancer: a meta-­analysis of observational studies. Korean J Fam Med 2018; 39:211–218.
39. Brandt J, et al. Benzodiazepines and Z-­drugs: an updated review of major adverse outcomes reported on in epidemiologic research. Drugs R 
D 2017; 17:493–507.
40. Peng TR, et al. Hypnotics and risk of cancer: a meta-­analysis of observational studies. Medicina (Kaunas) 2020; 56:513.
41. Wu CC, et al. Benzodiazepine use and the risk of dementia in the elderly population: an umbrella review of meta-­analyses. J Pers Med 2023; 
13:1485.
42. Mula M. The safety and tolerability of intranasal midazolam in epilepsy. Expert Rev Neurother 2014; 14:735–740.
43. Midazolam oral transmucosal route: an alternative to rectal diazepam for some children. Prescrire Int 2013; 22:173–177.
44. Penninga EI, et al. Adverse events associated with flumazenil treatment for the management of suspected benzodiazepine intoxication: a 
systematic review with meta-­analyses of randomised trials. Basic Clin Pharmacol Toxicol 2016; 118:37–44.